4-(3-(1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl)propoxy)-2-methylbenzamide | 1037753-90-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(3-(1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl)propoxy)-2-methylbenzamide
• 英文别名: 2-Methyl-4-[3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]propoxy]benzamide
• CAS: 1037753-90-4
• 化学式: C₂₁H₃₀N₄O₃
• 分子量: 386.494
• InChiKey: BNPFHLLYGSURDN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  94.5
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] HETEROCYCLIC GPCR AGONISTS<br/>[FR] AGONISTES DES RÉCEPTEURS COUPLÉS AUX PROTÉINES G (GPCR) HÉTÉROCYCLIQUES
  申请人：PROSIDION LTD

  公开号：WO2010004347A1

  公开（公告）日：2010-01-14

  Compounds of formula (I) or pharmaceutically acceptable salts thereof, are GPCR (GPR119) agonists and are useful as for the treatment of diabetes and obesity.

  化合物的化学式(I)或其药用盐是GPCR (GPR119)激动剂，可用于治疗糖尿病和肥胖。
• PIPERIDINE GPCR AGONISTS
  申请人：Bertram Lisa Sarah

  公开号：US20100022591A1

  公开（公告）日：2010-01-28

  Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.

  式(I)的化合物或其药学上可接受的盐，是GPCR激动剂，可用于治疗肥胖症和糖尿病。
• Piperidine GPCR agonists
  申请人：Prosidion Limited

  公开号：EP2383270A1

  公开（公告）日：2011-11-02

  GPCR AGONISTS Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.

  GPCR 激动剂 式(I)化合物： 或其药学上可接受的盐类是 GPCR 激动剂，可用于治疗肥胖症和糖尿病。
• COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2547339A1

  公开（公告）日：2013-01-23
• Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
  申请人：Eickelmann Peter

  公开号：US20130109703A1

  公开（公告）日：2013-05-02

  The present invention relates to combinations of DPP-4 inhibitors with GPR119 agonists, as well as to the use of these combinations for treating and/or preventing metabolic diseases, particularly diabetes (especially type 2 diabetes mellitus) and conditions related thereto.